Search research articles
Contact Us
Filters
Showing results (151-160 of 188) with videos related to
Page
of 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2019
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Kyung Hae Jung, Patricia LoRusso, Howard Burris, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 8, 2024
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors
Florentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, et al.
Journal of Translational Medicine
|
September 4, 2022
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy)
Paolo A Ascierto, Sanjiv S Agarwala, Christian Blank, et al.
Journal of Translational Medicine
|
July 20, 2023
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022)
Paolo A Ascierto, Antonio Avallone, Carlo Bifulco, et al.
Journal for Immunotherapy of Cancer
|
January 5, 2023
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Jason Chesney, Karl D Lewis, Harriet Kluger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 28, 2019
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
Ahmad A Tarhini, Sandra J Lee, F Stephen Hodi, et al.
Lancet (London, England)
|
July 19, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert, Antoni Ribas, Jedd D Wolchok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2016
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
Georgina V Long, Jeffrey S Weber, Jeffrey R Infante, et al.
The Lancet. Oncology
|
April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.
The New England Journal of Medicine
|
June 4, 2013
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
Omid Hamid, Caroline Robert, Adil Daud, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 188) with videos related to
Sort By:
Page
of 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2019
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Kyung Hae Jung, Patricia LoRusso, Howard Burris, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 8, 2024
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors
Florentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, et al.
Journal of Translational Medicine
|
September 4, 2022
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy)
Paolo A Ascierto, Sanjiv S Agarwala, Christian Blank, et al.
Journal of Translational Medicine
|
July 20, 2023
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022)
Paolo A Ascierto, Antonio Avallone, Carlo Bifulco, et al.
Journal for Immunotherapy of Cancer
|
January 5, 2023
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Jason Chesney, Karl D Lewis, Harriet Kluger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 28, 2019
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
Ahmad A Tarhini, Sandra J Lee, F Stephen Hodi, et al.
Lancet (London, England)
|
July 19, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert, Antoni Ribas, Jedd D Wolchok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2016
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
Georgina V Long, Jeffrey S Weber, Jeffrey R Infante, et al.
The Lancet. Oncology
|
April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.
The New England Journal of Medicine
|
June 4, 2013
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
Omid Hamid, Caroline Robert, Adil Daud, et al.
Page
of 19